Liberalization and protection: antidumping duties in the Indian pharmaceutical industry

In this paper we investigate whether antidumping (AD) actions in the Indian pharmaceutical industry have restricted trade from countries that were named to be dumping, or whether trade was diverted to other countries not named in these petitions. We found no evidence of trade diversion. It is bad news for consumers, as a restrictive trade policy translates into higher prices for the importing good. In a country where only 30% of the population can afford access to modern drugs, the trade effect due to AD laws must be carefully evaluated.